Abstracts tagged "Benefits"

Abstract Number: 1489 • 2019 ACR/ARP Annual Meeting
Impact of Apremilast on PsA Impact of Disease Core Components in Patients with a Limited Number of Active Joints: Results from a Real-World Study
Tim Jansen¹, Eric-Jan Kroot ², Arie van Vliet ³, Jan Pander ⁴ and Marijn Vis ⁵, ¹Viecuri MC, Venlo, Netherlands, ²Elkerliek, Helmond, Netherlands, ³Celgene, Utretcht, Netherlands, ⁴Celgene, Utrecht, Netherlands, ⁵ErasmusMC, Rotterdam, Netherlands
Background/Purpose: Recent data suggest that patients with moderately active psoriatic arthritis (PsA) and a limited number of active joints have a high likelihood of achieving…
Abstract Number: 1535 • 2018 ACR/ARHP Annual Meeting
Enhancing Patient Ability to Process and Use Information about Medication Risks and Benefits
Genevieve Hickey¹, Caprice Hunt¹, Molly Keebler², Delesha M. Carpenter³, Elizabeth (Blair) Solow⁴, Valerie Reyna⁵, W. Benjamin Nowell⁶, Cynthia Edmonds¹, Kimberlee O'Neill¹ and Susan J. Blalock¹, ¹Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Center for BrainHealth, University of Texas Dallas, Dallas, TX, ³Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Asheville, NC, ⁴UT Southwestern Rheumatology, Dallas, TX, ⁵Cornell University, Ithica, NY, ⁶Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose: Guidelines for the treatment of rheumatoid arthritis (RA) underscore the importance of an early and targeted approach to control inflammation. However, patients are often…
Abstract Number: 2809 • 2018 ACR/ARHP Annual Meeting
Skeletal Benefit/Risk of Long-Term Denosumab Therapy: A Virtual Twin Analysis of Fractures Prevented to Skeletal Safety Events Observed
Serge Ferrari¹, E. Michael Lewiecki², Peter W. Butler³, David L Kendler⁴, Nicola Napoli⁵, Shuang Huang³, Daria B Crittenden³, Nicola Pannacciulli³, E.S. Siris⁶ and Neil Binkley⁷, ¹Geneva University Hospital, Geneva, Switzerland, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ³Amgen Inc., Thousand Oaks, CA, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Campus Bio-Medico University of Rome, Rome, Italy, ⁶Columbia University Medical Center, New York, NY, ⁷University of Wisconsin–Madison Osteoporosis Clinical Center and Research Program, Madison, WI
Background/Purpose: Osteoporosis is a chronic disease, yet skeletal safety events—atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ)—remain a concern with long-term treatment. Ten…
Abstract Number: 1707 • 2016 ACR/ARHP Annual Meeting
Ustekinumab and the Comparative Risk for Acute Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis
Fenglong Xie¹, Lang Chen¹, Huifeng Yun² and Jeffrey R. Curtis³, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ³Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Ustekinumab (UST), an anti IL12/IL23 monoclonal antibody, is a relatively new biologic used for the treatment of psoriasis (PSO) and psoriatic arthritis (PSA). Its…
Abstract Number: 2505 • 2016 ACR/ARHP Annual Meeting
Thresholds of Benefit-Risk Trade-Offs from the Patient Perspective for Treatment Decisions in Moderate-to-Severe Rheumatoid Arthritis
M. Elaine Husni¹, Jenny Griffith², Keith Betts³, Yan Song⁴ and Arijit Ganguli², ¹Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Los Angeles, CA, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Given the increasing number of available treatments for RA with varying efficacy and safety profiles, it is critical to understand the level of trade-offs…
Abstract Number: 505 • 2014 ACR/ARHP Annual Meeting
A Structured Approach for Comparative Benefit-Risk Assessment of Rituximab for the Treatment of Rheumatoid Arthritis
Ani John¹, George Quartey¹, Patricia B. Lehane², Nicole Mairon³, Michael Schulte³, Ashwini Shewade¹, Carol Chung¹ and Dominic Borie¹, ¹Genentech, Inc, South San Francisco, CA, ²Roche Products Ltd, Welwyn Garden City, United Kingdom, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: Rituximab in combination with methotrexate (MTX) is indicated for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA) who have…
Abstract Number: 1425 • 2013 ACR/ARHP Annual Meeting
Discontinuation Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis Patients In Low Disease Activity: Persistent Benefits
Arthur Kavanaugh¹, Susan J. Lee^2,3, Daniel H. Solomon⁴, Jeffrey D. Greenberg⁵, Joel M. Kremer⁶, Lilian Soto⁷, Carol J. Etzel^8,9 and George W. Reed¹⁰, ¹University of California, San Diego, La Jolla, CA, ²University of California San Diego, La Jolla, CA, ³San Diego Veterans Affairs Medical Center, San Diego, CA, ⁴Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁵NYU Hospital for Joint Diseases, New York, NY, ⁶Center for Rheumatology, Albany Medical College, Albany, NY, ⁷University of California San Diego, San Diego, CA, ⁸Department of Epidemiology, UT MD Anderson, Houston, TX, ⁹PO Box 786, Corrona, LLC., Southborough, MA, ¹⁰Corrona, LLC., Southborough, MA
Background/Purpose: A key question is whether biologic agents can be stopped but clinical benefit maintained for rheumatoid arthritis (RA) patients (pts) in remission or low…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].